Chugai Pharmaceutical Co (TSE:4519) Tariff Resilience Score: 7/10 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4519 Chugai Pharmaceutical Co Ltd TSE:4519
95 GF Score
Price 円7,416.00
GF Value 円7,907.75
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Tariff Resilience Score?

Chugai Pharmaceutical Co TSE:4519 +2.83% 95 Tariff Resilience Score is 7 as of Jul. 26, 2026. GuruFocus rates TSE:4519 with a GF Score™ of 95/100 and a GF Value™ of 円7,907.75 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,027 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 97.08% on this metric.

Chugai Pharmaceutical Co has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Chugai Pharmaceutical Co has Chugai Pharmaceutical has moderate tariff exposure due to its global operations. However, its strong R&D and potential for tariff exemptions on pharmaceuticals provide resilience against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Chugai Pharmaceutical Co might have Highly Resilient.

Chugai Pharmaceutical Co  (TSE:4519) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Chugai Pharmaceutical Co Tariff Resilience Score Related Terms

TSE:4519 vs LLY, JNJ, ABBV: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chugai Pharmaceutical Co Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Tariff Resilience Score falls into.


TSE:4519
95GF Score
Chugai Pharmaceutical Co Ltd TSE:4519
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Chugai Pharmaceutical Co (TSE:4519) has a Tariff Resilience Score of 7 as of Jul. 26, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #30 out of 1027 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Chugai Pharmaceutical Co's Tariff Resilience Score too high?
Chugai Pharmaceutical Co's current Tariff Resilience Score is 7. Based on the distribution chart, Chugai Pharmaceutical Co ranks #30 out of 1027 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Tariff Resilience Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #30 out of 1027 companies for Tariff Resilience Score. This places Chugai Pharmaceutical Co in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Chugai Pharmaceutical Co's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (TSE:4519) is currently considered Fairly Valued. The stock's GF Value™ is 円7,907.75, compared to a current price of 円7,416.00 — trading 6.2% below its estimated fair value. The current Tariff Resilience Score is 7. Chugai Pharmaceutical Co's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Chugai Pharmaceutical Co (TSE:4519), the current Tariff Resilience Score is 7 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (TSE:4519) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of 円7,416.00 is trading 6.2% below its estimated GF Value™ of 円7,907.75. GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4519:

  • Tariff Resilience Score: 7
  • GF Value™: 円7,907.75 vs. price of 円7,416.00 (6.2% below fair value)
  • GF Score™: 95/100 with 1 warning sign

No single metric tells the full story. See the TSE:4519 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
95GF Score

Get the complete analysis for TSE:4519

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円7,416.00
Price
円7,907.75
GF Value